For patients suffering from acute kidney failure, for the intermittent procedures, intermittent hemodialysis is currently the standard of care in both the ICU and non-ICU settings such as the acute dialysis unit.1 This method while efficient, has been associated with hemodynamic instability.1 Over the last 25 years, there have been significant technological advances in the delivery of kidney replacement therapy particularly as it pertains to the critically ill population.2 In general most chronic hemodialysis patients in the acute and ICU settings are treated three times per week.
NxStage® products are used for IHD treatments in both the ICU and non-ICU settings and offer a wide range of benefits to this treatment procedure.
Risks and Responsibilities
Kidney replacement therapy, as with any medical therapy is not without risks. The decision of which therapy and medical device to use should be made by the physician, based on previous experience and on the individual facts and circumstances of the patient.
There is no literature demonstrating that one therapy is clinically better than the other.3
The use of anticoagulation is at the discretion of the prescribing physician.
